Iroko Pharmaceuticals, based at the Philadelphia Navy Yard, said Tuesday that its low-dose non-steroidal anti-inflammatory drug (NSAID) Vivlodex is now available by prescription at pharmacies. The Food and Drug Administration approved the capsules on Oct. 23 to treat osteoarthritis pain in 5 milligram and 10 milligram doses. The FDA has advocated for lower doses, where possible, of NSAIDS.
Iroko uses a licensed technology to reduce the particle size of existing NSAID pain medicines so that they dissolve faster and are effective at lower doses, the company said. Vivlodex was approved to treat pain associated with osteoarthritis. About 27 million Americans live with osteoarthritis, the company said.
Traditional NSAIDs are a category of medicines that include over-the-counter names Advil and Alleve. Iroko has two other low-dose NSAID medicines that use the same small-particle technology and were approved by the FDA in 2013 and 2014.
Iroko, founded in 2007 by Phoenix IP Ventures, a Philadelphia private equity and venture capital firm, has 164 full-time employees.